FDA TEMPO Pilot — Generative AI Medical Devices Path to Patients Before Authorization
CONCEPTThe FDA's TEMPO (Total, Expedited, Modernized Pathway for Optimization) pilot creates an accelerated regulatory pathway for generative AI-enabled medical devices, allowing qualified products to reach patients before full pre-market authorization is complete. This represents a significant shift in FDA strategy, balancing innovation speed with safety oversight. Under TEMPO, developers can deploy AI devices in clinical settings under specific conditions: (1) real-world evidence collection during deployment; (2) continuous monitoring and performance validation; (3) predetermined triggers for regulatory action if safety signals emerge; and (4) post-market adaptation authority allowing AI models to evolve based on clinical data. The pilot addresses a core FDA challenge: traditional pre-market authorization timelines (2-3 years) are misaligned with AI development cycles and the rapid evolution of large language models. TEMPO enables faster patient access to beneficial AI tools while maintaining safety oversight through post-market surveillance and adaptive governance. However, the approach raises liability questions about which parties bear responsibility if AI performance degrades after deployment. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.